Does TRANSCAT INC have an economic moat?

Based on its FY2026 SEC filings, the Moat Index scores TRANSCAT INC (TRNS) 38.8 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 39, returns on capital 35, balance-sheet safety 24, capital discipline 60.

Is TRNS stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $26.83 per share versus a recent price of $87.90 — 228% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has TRNS's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 38.8 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

TRANSCAT INC

TRNS · Healthcare · $820.5M mkt cap · FY2026 filings · No moat ·

Doesn't clear the bar

No moat

The four filters

Pricing power39

Median gross margin 27.6% over 10y, stable.

Returns on capital35

Median ROIC 8.9%, above the 9% hurdle in 50% of years.

Balance-sheet safety24

Net debt/EBITDA 2.4x, interest coverage 3x.

Capital discipline60

Owner earnings +12.9%/yr, share count growing (dilution).

Margin of safety

Above valueOn sale

228% above value

Owner earnings (normalized): $13.9M
Est. intrinsic value / share: $26.83
Recent price: $87.90
Discount to value: 228% above value

Conservative model: 9% discount rate, 4% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for TRNS yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale38.8 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — TRNS has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#263 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#261ALNY ALNYLAM PHARMACEUTICALS, INC.39.0 out of 100, No moatNo moat
#262NUWE Nuwellis, Inc.38.9 out of 100, No moatNo moat
#264LAB STANDARD BIOTOOLS INC.38.5 out of 100, No moatNo moat
#265CLPT CLEARPOINT NEURO, INC.38.5 out of 100, No moatNo moat

Compare TRNS with its nearest peers →All Healthcare companies on the Index →

Common questions about TRNS

Does TRANSCAT INC have an economic moat?: Based on its FY2026 SEC filings, the Moat Index scores TRANSCAT INC (TRNS) 38.8 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 39, returns on capital 35, balance-sheet safety 24, capital discipline 60.
Is TRNS stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $26.83 per share versus a recent price of $87.90 — 228% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has TRNS's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 38.8 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows TRNS’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/TRNS"
  width="340" height="150" style="border:0"
  title="TRNS Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell TRNS. See the disclaimer.